Zacks Investment Research Upgrades Sucampo Pharmaceuticals, Inc. (SCMP) to Buy

Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a research report issued on Tuesday. The brokerage presently has a $11.00 price objective on the biopharmaceutical company’s stock. Zacks Investment Research‘s price objective would indicate a potential upside of 9.73% from the stock’s previous close.

According to Zacks, “Sucampo is focused on expanding Amitiza’s label and penetrating new markets. Also, Sucampo’s collaborations with firms like Takeda and Mylan for Amitiza’s commercialization is a big positive. Also, through the agreement with Cancer Prevention Pharmaceuticals, Sucampo acquired an exclusive option to develop and commercialize its combination, CPP-1X/sulindac, in North America. Moreover, the Vtesse acquisition added a pivotal program in Niemann-Pick Disease type C1 to its pipeline. However, dependence of Sucampo on Amitiza for growth is concerning with few companies trying to market and sell generic version of Amitiza. A decline in Amitiza's sales will adversely impact the top line. Moreover, it had its share of pipeline setbacks. Shares of the company have underperformed the industry. Estimates have remained stable ahead of the Q3 earnings results. The company has a mixed record of earnings surprises in the recent quarters.”

Other equities research analysts have also recently issued research reports about the stock. UBS AG dropped their price objective on shares of Sucampo Pharmaceuticals from $19.00 to $15.00 and set a “buy” rating on the stock in a research note on Thursday, October 12th. Maxim Group reaffirmed a “buy” rating and set a $23.00 price objective (up previously from $21.00) on shares of Sucampo Pharmaceuticals in a research note on Tuesday, August 8th. ValuEngine raised shares of Sucampo Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Friday, June 23rd. Roth Capital set a $30.00 price objective on shares of Sucampo Pharmaceuticals and gave the stock a “buy” rating in a research note on Thursday, August 3rd. Finally, TheStreet cut shares of Sucampo Pharmaceuticals from a “c+” rating to a “d” rating in a research note on Wednesday, August 2nd. Three investment analysts have rated the stock with a hold rating and seven have given a buy rating to the company. Sucampo Pharmaceuticals has an average rating of “Buy” and a consensus target price of $16.50.

Shares of Sucampo Pharmaceuticals (NASDAQ:SCMP) traded up 3.00% during trading on Tuesday, reaching $10.30. 219,804 shares of the company’s stock traded hands. The stock’s market cap is $477.15 million. Sucampo Pharmaceuticals has a one year low of $9.30 and a one year high of $17.55. The company has a 50 day moving average price of $11.61 and a 200-day moving average price of $10.71.

Sucampo Pharmaceuticals (NASDAQ:SCMP) last issued its quarterly earnings data on Wednesday, August 2nd. The biopharmaceutical company reported $0.28 EPS for the quarter, topping analysts’ consensus estimates of $0.22 by $0.06. The business had revenue of $59.90 million for the quarter, compared to analysts’ expectations of $56.44 million. Sucampo Pharmaceuticals had a negative net margin of 61.99% and a positive return on equity of 56.58%. The business’s revenue was up 15.3% on a year-over-year basis. During the same quarter last year, the company earned $0.24 EPS. On average, equities research analysts expect that Sucampo Pharmaceuticals will post $1.01 EPS for the current fiscal year.

ILLEGAL ACTIVITY WARNING: This piece of content was originally reported by The Ledger Gazette and is the property of of The Ledger Gazette. If you are viewing this piece of content on another website, it was stolen and republished in violation of international trademark & copyright legislation. The legal version of this piece of content can be viewed at https://ledgergazette.com/2017/10/17/zacks-investment-research-upgrades-sucampo-pharmaceuticals-inc-scmp-to-buy.html.

In other Sucampo Pharmaceuticals news, insider Jones W. Bryan bought 4,700 shares of the firm’s stock in a transaction dated Friday, August 4th. The shares were purchased at an average price of $10.60 per share, for a total transaction of $49,820.00. Following the transaction, the insider now directly owns 4,700 shares of the company’s stock, valued at approximately $49,820. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, major shareholder Sachiko Kuno sold 1,000,000 shares of the stock in a transaction that occurred on Monday, September 11th. The shares were sold at an average price of $12.00, for a total value of $12,000,000.00. The disclosure for this sale can be found here. Company insiders own 4.13% of the company’s stock.

Several large investors have recently made changes to their positions in the company. Louisiana State Employees Retirement System lifted its position in shares of Sucampo Pharmaceuticals by 1.0% during the 2nd quarter. Louisiana State Employees Retirement System now owns 10,200 shares of the biopharmaceutical company’s stock valued at $107,000 after buying an additional 100 shares in the last quarter. Arizona State Retirement System lifted its position in shares of Sucampo Pharmaceuticals by 1.6% during the 2nd quarter. Arizona State Retirement System now owns 13,100 shares of the biopharmaceutical company’s stock valued at $138,000 after buying an additional 200 shares in the last quarter. Capstone Asset Management Co. lifted its position in shares of Sucampo Pharmaceuticals by 2.1% during the 2nd quarter. Capstone Asset Management Co. now owns 12,360 shares of the biopharmaceutical company’s stock valued at $130,000 after buying an additional 260 shares in the last quarter. Texas Permanent School Fund lifted its position in shares of Sucampo Pharmaceuticals by 2.2% during the 2nd quarter. Texas Permanent School Fund now owns 18,319 shares of the biopharmaceutical company’s stock valued at $192,000 after buying an additional 398 shares in the last quarter. Finally, Rhumbline Advisers lifted its position in shares of Sucampo Pharmaceuticals by 0.9% during the 2nd quarter. Rhumbline Advisers now owns 48,810 shares of the biopharmaceutical company’s stock valued at $513,000 after buying an additional 423 shares in the last quarter. Hedge funds and other institutional investors

According to Zacks, “Sucampo is focused on expanding Amitiza’s label and penetrating new markets. Also, Sucampo’s collaborations with firms like Takeda and Mylan for Amitiza’s commercialization is a big positive. Also, through the agreement with Cancer Prevention Pharmaceuticals, Sucampo acquired an exclusive option to develop and commercialize its combination, CPP-1X/sulindac, in North America. Moreover, the Vtesse acquisition added a pivotal program in Niemann-Pick Disease type C1 to its pipeline. However, dependence of Sucampo on Amitiza for growth is concerning with few companies trying to market and sell generic version of Amitiza. A decline in Amitiza's sales will adversely impact the top line. Moreover, it had its share of pipeline setbacks. Shares of the company have underperformed the industry. Estimates have remained stable ahead of the Q3 earnings results. The company has a mixed record of earnings surprises in the recent quarters.”

Other equities research analysts have also recently issued research reports about the stock. UBS AG dropped their price objective on shares of Sucampo Pharmaceuticals from $19.00 to $15.00 and set a “buy” rating on the stock in a research note on Thursday, October 12th. Maxim Group reaffirmed a “buy” rating and set a $23.00 price objective (up previously from $21.00) on shares of Sucampo Pharmaceuticals in a research note on Tuesday, August 8th. ValuEngine raised shares of Sucampo Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Friday, June 23rd. Roth Capital set a $30.00 price objective on shares of Sucampo Pharmaceuticals and gave the stock a “buy” rating in a research note on Thursday, August 3rd. Finally, TheStreet cut shares of Sucampo Pharmaceuticals from a “c+” rating to a “d” rating in a research note on Wednesday, August 2nd. Three investment analysts have rated the stock with a hold rating and seven have given a buy rating to the company. Sucampo Pharmaceuticals has an average rating of “Buy” and a consensus target price of $16.50.

Shares of Sucampo Pharmaceuticals (NASDAQ:SCMP) traded up 3.00% during trading on Tuesday, reaching $10.30. 219,804 shares of the company’s stock traded hands. The stock’s market cap is $477.15 million. Sucampo Pharmaceuticals has a one year low of $9.30 and a one year high of $17.55. The company has a 50 day moving average price of $11.61 and a 200-day moving average price of $10.71.

Sucampo Pharmaceuticals (NASDAQ:SCMP) last issued its quarterly earnings data on Wednesday, August 2nd. The biopharmaceutical company reported $0.28 EPS for the quarter, topping analysts’ consensus estimates of $0.22 by $0.06. The business had revenue of $59.90 million for the quarter, compared to analysts’ expectations of $56.44 million. Sucampo Pharmaceuticals had a negative net margin of 61.99% and a positive return on equity of 56.58%. The business’s revenue was up 15.3% on a year-over-year basis. During the same quarter last year, the company earned $0.24 EPS. On average, equities research analysts expect that Sucampo Pharmaceuticals will post $1.01 EPS for the current fiscal year.

ILLEGAL ACTIVITY WARNING: This piece of content was originally reported by The Ledger Gazette and is the property of of The Ledger Gazette. If you are viewing this piece of content on another website, it was stolen and republished in violation of international trademark & copyright legislation. The legal version of this piece of content can be viewed at https://ledgergazette.com/2017/10/17/zacks-investment-research-upgrades-sucampo-pharmaceuticals-inc-scmp-to-buy.html.

In other Sucampo Pharmaceuticals news, insider Jones W. Bryan bought 4,700 shares of the firm’s stock in a transaction dated Friday, August 4th. The shares were purchased at an average price of $10.60 per share, for a total transaction of $49,820.00. Following the transaction, the insider now directly owns 4,700 shares of the company’s stock, valued at approximately $49,820. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, major shareholder Sachiko Kuno sold 1,000,000 shares of the stock in a transaction that occurred on Monday, September 11th. The shares were sold at an average price of $12.00, for a total value of $12,000,000.00. The disclosure for this sale can be found here. Company insiders own 4.13% of the company’s stock.

Several large investors have recently made changes to their positions in the company. Louisiana State Employees Retirement System lifted its position in shares of Sucampo Pharmaceuticals by 1.0% during the 2nd quarter. Louisiana State Employees Retirement System now owns 10,200 shares of the biopharmaceutical company’s stock valued at $107,000 after buying an additional 100 shares in the last quarter. Arizona State Retirement System lifted its position in shares of Sucampo Pharmaceuticals by 1.6% during the 2nd quarter. Arizona State Retirement System now owns 13,100 shares of the biopharmaceutical company’s stock valued at $138,000 after buying an additional 200 shares in the last quarter. Capstone Asset Management Co. lifted its position in shares of Sucampo Pharmaceuticals by 2.1% during the 2nd quarter. Capstone Asset Management Co. now owns 12,360 shares of the biopharmaceutical company’s stock valued at $130,000 after buying an additional 260 shares in the last quarter. Texas Permanent School Fund lifted its position in shares of Sucampo Pharmaceuticals by 2.2% during the 2nd quarter. Texas Permanent School Fund now owns 18,319 shares of the biopharmaceutical company’s stock valued at $192,000 after buying an additional 398 shares in the last quarter. Finally, Rhumbline Advisers lifted its position in shares of Sucampo Pharmaceuticals by 0.9% during the 2nd quarter. Rhumbline Advisers now owns 48,810 shares of the biopharmaceutical company’s stock valued at $513,000 after buying an additional 423 shares in the last quarter. Hedge funds and other institutional investors own 55.46% of the company’s stock.

About Sucampo Pharmaceuticals

Sucampo Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of pharmaceutical products. Its primary focus areas are gastroenterology, ophthalmology and oncology-related disorders. Its product candidates include VTS-270, Lubiprostone (AMITIZA), Unoprostone is opropyl (RESCULA) and CPP-1X/sulindac combination product.

Analyst Recommendations for Sucampo Pharmaceuticals (NASDAQ:SCMP)

Receive News & Ratings for Sucampo Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sucampo Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply